This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Roelofs, A. J. Articles by Rogers, M. J. Search for Related Content PubMed PubMed Citation Articles by Roelofs, A. J. Articles by Rogers, M. J.

Molecular Mechanisms of Action of Bisphosphonates: Current Status

Authors' Affiliation: Bone Research Group, Institute of Medical Sciences, University of Aberdeen, Aberdeen, United Kingdom

Requests for reprints: Michael J. Rogers, Bone Research Group, Institute of Medical Sciences, University of Aberdeen, Aberdeen AB25 2ZD, United Kingdom. Phone: 44-1244-554842; Fax: 44-1224-559533; E-mail: m.j.rogers{at}abdn.ac.uk.

Purpose: Bisphosphonates are currently the most important class of antiresorptive agents used in the treatment of metabolic bone diseases, including tumor-associated osteolysis and hypercalcemia. These compounds have high affinity for calcium ions and therefore target bone mineral, where they are internalized by bone-resorbing osteoclasts and inhibit osteoclast function.

Experimental Design: This article reviews the pharmacology of bisphosphonates and the relationship between chemical structure and antiresorptive potency. We also describe new insights into their intracellular molecular mechanisms of action, methods for assessing the effects of bisphosphonates on protein prenylation, and their potential as direct antitumor agents.

Results: Nitrogen-containing bisphosphonates act intracellularly by inhibiting farnesyl diphosphate synthase, an enzyme of the mevalonate pathway, thereby preventing prenylation of small GTPase signaling proteins required for normal cellular function. Inhibition of farnesyl diphosphate synthase also seems to account for their antitumor effects observed in vitro and for the activation of , T cells, a feature of the acute-phase response to bisphosphonate treatment in humans. Bisphosphonates that lack a nitrogen in the chemical structure do not inhibit protein prenylation and have a different mode of action that seems to involve primarily the formation of cytotoxic metabolites in osteoclasts.

Conclusions: Bisphosphonates are highly effective inhibitors of bone resorption that selectively affect osteoclasts in vivo but could also have direct effects on other cell types, such as tumor cells. After >30 years of clinical use, their molecular mechanisms of action on osteoclasts are finally becoming clear but their exact antitumor properties remain to be clarified.

This article has been cited by other articles:

				N. D. Toussaint, G. J. Elder, and P. G. Kerr Bisphosphonates in Chronic Kidney Disease; Balancing Potential Benefits and Adverse Effects on Bone and Soft Tissue Clin. J. Am. Soc. Nephrol., January 1, 2009; 4(1): 221 - 233. [Abstract] [Full Text] [PDF]

				A. Yano, S. Tsutsumi, S. Soga, M.-J. Lee, J. Trepel, H. Osada, and L. Neckers Inhibition of Hsp90 activates osteoclast c-Src signaling and promotes growth of prostate carcinoma cells in bone PNAS, October 7, 2008; 105(40): 15541 - 15546. [Abstract] [Full Text] [PDF]

				F. P. Coxon An Update on the Pharmacology of Bisphosphonates and Analogues with Lower Bone Affinity IBMS BoneKEy, October 1, 2008; 5(10): 357 - 369. [Abstract] [Full Text] [PDF]

				S. J. Suratwala, S. K. Cho, J. J. van Raalte, S. H. Park, S. W. Seo, S.-S. Chang, T. R. Gardner, and F. Y.-I. Lee Enhancement of Periprosthetic Bone Quality with Topical Hydroxyapatite-Bisphosphonate Composite J. Bone Joint Surg. Am., October 1, 2008; 90(10): 2189 - 2196. [Abstract] [Full Text] [PDF]

				X. Li and L. K. McCauley Osteonecrosis of the Jaw: Meeting Report from Skeletal Complications of Malignancy V: October 25-27, 2007 in Philadelphia, Pennsylvania, USA IBMS BoneKEy, August 1, 2008; 5(8): 289 - 293. [Full Text] [PDF]

				I. R. Reid Pathogenesis of Osteonecrosis of the Jaw IBMS BoneKEy, February 1, 2008; 5(2): 69 - 77. [Abstract] [Full Text] [PDF]

				K. Olson and C. Van Poznak Significance and impact of bisphosphonate-induced acute phase responses Journal of Oncology Pharmacy Practice, December 1, 2007; 13(4): 223 - 229. [Abstract] [PDF]